Related references
Note: Only part of the references are listed.Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
In vitro metabolism of 2-[6-(4-Chlorophenyl)-2,2-dimethyl-7phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] acetic acid (licofelone, ML3000), an inhibitor of cyclooxygenase-1 and-2 and 5-lipoxygenase
Wolfgang Albrecht et al.
DRUG METABOLISM AND DISPOSITION (2008)
Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade
Simona Tavolari et al.
CARCINOGENESIS (2008)
Lipoxygenase metabolism: roles in tumor progression and survival
Graham P. Pidgeon et al.
CANCER AND METASTASIS REVIEWS (2007)
Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells
Saswati Hazra et al.
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS (2007)
A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours
Tara Baetz et al.
INVESTIGATIONAL NEW DRUGS (2007)
Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase
Saswati Hazra et al.
MOLECULAR PHARMACOLOGY (2007)
Dynamic simulations on the arachidonic acid metabolic network
Kun Yang et al.
PLOS COMPUTATIONAL BIOLOGY (2007)
Peroxisome Proliferator-Activated Receptors in Lung Cancer
Venkateshwar G. Keshamouni et al.
PPAR RESEARCH (2007)
The cardiovascular effects of the thiazolidinediones: a review of the clinical data
Aaron S. Kelly et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2007)
Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics?
ShouWei Han et al.
ANTI-CANCER DRUGS (2007)
Leukotriene B4 receptor antagonist LY293111 induces S-phase cell cycle arrest and apoptosis in human pancreatic cancer cells
Wei-Gang Tong et al.
ANTI-CANCER DRUGS (2007)
Licofelone-A novel analgesic and anti-inflammatory agent
S. K. Kulkarni et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2007)
COX-2/5-LOX dual acting anti-inflammatory drugs in cancer chemotherapy
Laurence Goossens et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2007)
What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis?
G. Fuerstenberger et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells
Fabio Cianchi et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Effects of PPARγ agonists on cell survival and focal adhesions in a Chinese thyroid carcinoma cell line
Ying Chen et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2006)
PPAR-γ agonist increase gefitinib's antitumor activity through PTEN expression
SY Lee et al.
LUNG CANCER (2006)
Rosiglitazone suppresses human lung carcinoma cell growth through PPAR-γ-dependent and PPARγ-independent signal pathways
SW Han et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors
MS Shaik et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities
T Grosser et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs
JA Mitchell et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation
W Zhang et al.
LEUKEMIA (2005)
Designed multiple ligands. An emerging drug discovery paradigm
R Morphy et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Peroxisome proliferator-activated receptor-γ ligands suppress fibronectin gene expression in human lung carcinoma cells:: involvement of both CRE and Sp1
SW Han et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2005)
Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors
GK Schwartz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Effects of selective COX-2 and 5-LOX inhibition on prostaglandin and leukotriene synthesis in ductal pancreatic cancer in Syrian hamster
JI Gregor et al.
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS (2005)
Critical role of peroxisome proliferator-activated receptor γ on anoikis and invasion of squamous cell carcinoma
T Masuda et al.
CLINICAL CANCER RESEARCH (2005)
A novel anti-pancreatic cancer agent LY293111
XZ Ding et al.
ANTI-CANCER DRUGS (2005)
Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition
I Avis et al.
CANCER RESEARCH (2005)
Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke
YN Ye et al.
CARCINOGENESIS (2005)
Peroxisome proliferator-activated receptor-γ ligands inhibit α5 integrin gene transcription in non-small cell lung carcinoma cells
SW Han et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2005)
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial
RS Bresalier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery
NA Nussmeier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention
SD Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib
N Li et al.
CLINICAL CANCER RESEARCH (2005)
Formulation and evaluation of aerosolized celecoxib for the treatment of lung cancer
A Haynes et al.
PHARMACEUTICAL RESEARCH (2005)
Peroxisome proliferator-activated receptor-γ (PPARγ) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC)
Y Bren-Mattison et al.
ONCOGENE (2005)
Superiority of the gastroduodenal safety profile of licofelone over rofecoxib, a COX-2 selective inhibitor, in dogs
M Moreau et al.
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS (2005)
Combined lipoxygenase/cyclo-oxygenase inhibition in the elderly - The example of licofelone
AFG Cicero et al.
DRUGS & AGING (2005)
The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: Results from a randomized, controlled trial
P Bias et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2004)
Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor γ in human lung carcinoma cells
SW Han et al.
CLINICAL CANCER RESEARCH (2004)
Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib
CR Schroeder et al.
CANCER BIOLOGY & THERAPY (2004)
Effect of LY293111 in combination with gemcitabine in colonic cancer
R Hennig et al.
CANCER LETTERS (2004)
Cytosolic phospholipase A2 group IVα but not secreted phospholipase A2 group IIA, V, or X induces interleukin-8 and cyclooxygenase-2 gene and protein expression through peroxisome proliferator-activated receptors γ 1 and 2 in human lung cells
R Pawliczak et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Modulation of pulmonary leukotriene B4 production by cyclooxygenase-2 inhibitors and lipopolysaccharide
JT Mao et al.
CLINICAL CANCER RESEARCH (2004)
Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-γ and retinoid X receptor heterodimer
EY Park et al.
CANCER RESEARCH (2004)
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic
TD Warner et al.
FASEB JOURNAL (2004)
The importance of the eicosanoid pathway in lung cancer
JJ Laskin et al.
LUNG CANCER (2003)
85-kDa cytosolic phospholipase A2 mediates peroxisome proliferator-activated receptor γ activation in human lung epithelial cells
R Pawliczak et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
New trends in dual 5-LOX/COX inhibition
X de Leval et al.
CURRENT MEDICINAL CHEMISTRY (2002)
Activation of peroxisome proliferator-activated receptor-γ stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells
T Satoh et al.
ONCOGENE (2002)
Differentiating members of the thiazolidinedione class: a focus on safety
HE Lebovitz
DIABETES-METABOLISM RESEARCH AND REVIEWS (2002)
Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells - Involvement of phosphatidylinositol 3-kinase/Akt pathway
MT Lin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2
RA Gupta et al.
NATURE REVIEWS CANCER (2001)
Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions
I Avis et al.
FASEB JOURNAL (2001)
Inhibition of peroxisome-proliferator-activated receptor (PPAR)α by MK886
JP Kehrer et al.
BIOCHEMICAL JOURNAL (2001)
Anti-inflammatory drugs: New multitarget compounds to face an old problem. The dual inhibition concept
F Celotti et al.
PHARMACOLOGICAL RESEARCH (2001)
Peroxisome proliferator-activated receptor-γ ligands inhibit adipocyte 11β-hydroxysteroid dehydrogenase type 1 expression and activity
J Berger et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Intracellular unesterified arachidonic acid signals apoptosis
Y Cao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation?
SH Hong et al.
FASEB JOURNAL (2000)
Share Paper
